JPRN-UMIN000001487已完成2 期
A phase II study of gemcitabine in pancreatic endocrine tumor - A phase II study of gemcitabine in pancreatic endocrine tumor
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Intestinal pneumonia or lung fibrosis 2) Massive pleural or abdominal effusion 3) Symptomatic brain metastasis 4) History of other active malignancy 5) Severe infection 6) Severe complication 7) Pregnancy or the desire to preserve fecundity 8) uncontrollable endocrine symptom 9) Inadequate physical condition, as diagnosed by primary physician
研究者
相似试验
已完成
不适用
Research of gemcitabine sensitivity in pancreatic cancer.Advanced pancreatic cancerJPRN-UMIN000006840Gifu University Dept. of Gastroenterology100
已完成
1 期
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the PancreasPancreatic CancerNCT01128296Amer Zureikat35
终止
早期 1 期
Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the PancreasPancreatic CancerNCT01276613M.D. Anderson Cancer Center18
撤回
2 期
The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.Pancreas AdenocarcinomaNCT04045730Yale University
已完成
2 期
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic CancerPancreatic CancerNCT00733850KangLaiTe USA85